Ropinirole hydrochloride for amyotrophic lateral sclerosis: a single-center, randomized, double-blind, placebo-controlled phase 1/2a feasibility trial
Published: 21 April 2023| Version 1 | DOI: 10.17632/jsfcx3vz8s.1
Contributor:
Satoru MorimotoDescription
These data are the deposited supplemental information for the article entitled "Ropinirole hydrochloride for amyotrophic lateral sclerosis: a single-center, randomized, double-blind, placebo-controlled phase 1/2a feasibility trial" by Morimoto and Takahashi et al. in Cell Stem Cell.
Files
Institutions
Keio Gijuku Daigaku - Shinanomachi Campus
Categories
Drug Discovery, Clinical Trial, Induced Pluripotent Stem Cell, Amyotrophic Lateral Sclerosis, Dopamine Receptor Agonist
Funders
- Japan Agency for Medical Research and DevelopmentJapanGrant ID: JP22bm0804003, JP20ek0109395, JP20ek0109329, JP22ek0109493, JP22wm0425009
- Japan Society for the Promotion of ScienceJapanGrant ID: JP22K15736, JP21H05273, JP22K07500, JP20H00485, JP21H05273, JP16H06277
- K Pharma, Inc.
- YUKIHIKO MIYATA MEMORIAL TRUST FOR ALS RESEARCH
- Okasan-Kato Foundation Research Grant
- Yoshio Koide Grant, Japan ALS Association
- Intramural Research Grant for Neurological Psychiatric Disorders from National Centre of Neurology and Psychiatry (NCNP)